Fat Loss + Lean Muscle Cycle: A popular stack for women includes Clenbutrol for thermogenic fat burning, Anvarol for lean ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...

Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the ...

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release second quarter 2025 results on Tuesday, July 29, 2025, ...

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, ...

About BriaCell Therapeutics BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

The Unit Shares and Warrants, and any securities issuable upon conversion or exercise thereof, are subject to a four-month hold period under applicable ‎securities laws in Canada. The Offering is ...

The Series A-1 warrants have an exercise price of $1.90 per share, are exercisable upon issuance and expire five years thereafter. The short-term Series A-2 warrants have an exercise price of $1.90 ...

Investors subscribing for Series E Preferred Stock will receive an annual 12% dividend rate, which will accrue and be paid quarterly. The Series E Preferred Stock is convertible into a new class of GH ...

At the core of Quetzal’s mission is a belief that cutting-edge science, guided by proven leadership, can redefine what’s possible in treatment for conditions like Acute Promyelocytic Leukemia (“APL”) ...

About eMI eMI Aesthetics is an innovative AI-powered platform that empowers users to explore aesthetic treatments visually, privately, and confidently. With no downloads, instant simulation, and ...

Quarterly consolidated revenue Our second-quarter revenue reached €363.1 million, marking a +6.4% increase at constant exchange rates and scope compared to the same period in 2024. This strong ...